

Publications by Research Area B11

1. Begum N. J., Glatting G., **Eiber M.**, Beer A. J., Kletting P. (2021). An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands. *Nuklearmedizin*, 60(1), 33-37. doi:10.1055/a-1253-1535
2. Begum N. J., Glatting G., Wester H. J., **Eiber M.**, Beer A. J., Kletting P. (2019). The effect of ligand amount, affinity and internalization on PSMA- targeted imaging and therapy: A simulation study using a PBPK model. *Sci Rep*, 9(1), 20041. doi:10.1038/s41598-019-56603-8
3. Bieth M., Kronke M., Tauber R., Dahlbender M., Retz M., Nekolla S. G., Menze B., Maurer T., **Eiber M.**, Schwaiger M. (2017). Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using (68)Ga-PSMA PET/CT. *J Nucl Med*, 58(10), 1632-1637. doi:10.2967/jnumed.116.189050
4. Calais J., Ceci F., **Eiber M.**, Hope T. A., Hofman M. S., Rischpler C., Bach-Gansmo T., Nanni C., Savir-Baruch B., Elashoff D., Grogan T., Dahlbom M., Slavik R., Gartmann J., Nguyen K., Lok V., Jadvar H., Kishan A. U., Rettig M. B., Reiter R. E., Fendler W. P., Czernin J. (2019). (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single- centre, single-arm, comparative imaging trial. *Lancet Oncol*, 20(9), 1286-1294. doi:10.1016/s1470-2045(19)30415-2
5. Calais J., Czernin J., Cao M., Kishan A. U., Hegde J. V., Shaverdian N., Sandler K., Chu F. I., King C. R., Steinberg M. L., Rauscher I., Schmidt-Hegemann N. S., Poeppel T., Hetkamp P., Ceci F., Herrmann K., Fendler W. P., **Eiber M.**, Nickols N. G. (2018). (68)Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. *J Nucl Med*, 59(2), 230-237. doi:10.2967/jnumed.117.201749
6. Calais J., Fendler W. P., **Eiber M.**, Gartmann J., Chu F. I., Nickols N. G., Reiter R. E., Rettig M. B., Marks L. S., Ahlering T. E., Huynh L. M., Slavik R., Gupta P., Quon A., Allen-Auerbach M. S., Czernin J., Herrmann K. (2018). Impact of (68)Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. *J Nucl Med*, 59(3), 434-441. doi:10.2967/jnumed.117.202945
7. Calais J., Fendler W. P., Herrmann K., **Eiber M.**, Ceci F. (2018). Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. *J Nucl Med*, 59(5), 789-794. doi:10.2967/jnumed.117.203257
8. Calais J., Kishan A. U., Cao M., Fendler W. P., **Eiber M.**, Herrmann K., Ceci F.,

- Reiter R. E., Rettig M. B., Hegde J. V., Shaverdian N., King C. R., Steinberg M. L., Czernin J., Nickols N. G. (2018). Potential Impact of (68)Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. *J Nucl Med*, 59(11), 1714-1721. doi:10.2967/jnumed.118.209387
9. **Eiber M.**, Herrmann K., Calais J., Hadaschik B., Giesel F. L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W. A., Fendler W. P. (2018). Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. *J Nucl Med*, 59(3), 469-478. doi:10.2967/jnumed.117.198119
10. **Eiber M.**, Kroenke M., Wurzer A., Ulbrich L., Jooss L., Maurer T., Horn T., Schiller K., Langbein T., Buschner G., Wester H. J., Weber W. (2020). (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. *J Nucl Med*, 61(5), 696-701. doi:10.2967/jnumed.119.234914
11. Gafita A., Bieth M., Kronke M., Tetteh G., Navarro F., Wang H., Gunther E., Menze B., Weber W. A., **Eiber M.** (2019). qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using (68)Ga-PSMA11 PET/CT. *J Nucl Med*, 60(9), 1277-1283. doi:10.2967/jnumed.118.224055
12. Gafita A., Calais J., Franz C., Rauscher I., Wang H., Roberstson A., Czernin J., Weber W. A., **Eiber M.** (2019). Evaluation of SUV normalized by lean body mass (SUL) in (68)Ga-PSMA11 PET/CT: a bi-centric analysis. *EJNMMI Res*, 9(1), 103. doi:10.1186/s13550-019-0572-z
13. Gafita A., Fendler W. P., Hui W., Sandhu S., Weber M., Esfandiari R., Calais J., Rauscher I., Rathke H., Tauber R., Delpassand E. S., Weber W. A., Herrmann K., Czernin J., **Eiber M.**, Hofman M. S. (2020). Efficacy and Safety of (177)Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. *Eur Urol*, 78(2), 148-154. doi:10.1016/j.eururo.2020.05.004
14. Gafita A., Rauscher I., Retz M., Knorr K., Heck M., Wester H. J., D'Alessandria C., Weber W. A., **Eiber M.**, Tauber R. (2019). Early Experience of Rechallenge (177)Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. *J Nucl Med*, 60(5), 644-648. doi:10.2967/jnumed.118.215715
15. Giesel F. L., Knorr K., Spohn F., Will L., Maurer T., Flechsig P., Neels O., Schiller K., Amaral H., Weber W. A., Haberkorn U., Schwaiger M., Kratochwil C., Choyke P., Kramer V., Kopka K., **Eiber M.** (2019). Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. *J Nucl Med*, 60(3), 362-368. doi:10.2967/jnumed.118.212233

16. Heck M. M., Tauber R., Schwaiger S., Retz M., D'Alessandria C., Maurer T., Gafita A., Wester H. J., Gschwend J. E., Weber W. A., Schwaiger M., Knorr K., **Eiber M.** (2019). Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. *Eur Urol*, 75(6), 920-926. doi:10.1016/j.eururo.2018.11.016
17. Hofman M. S., Hicks R. J., Maurer T., **Eiber M.** (2018). Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. *Radiographics*, 38(1), 200-217. doi:10.1148/rg.2018170108.
18. Kletting P., Thieme A., Eberhardt N., Rinscheid A., D'Alessandria C., Allmann J., Wester H. J., Tauber R., Beer A. J., Glatting G., **Eiber M.** (2019). Modeling and Predicting Tumor Response in Radioligand Therapy. *J Nucl Med*, 60(1), 65-70. doi:10.2967/jnumed.118.210377
19. Kraft P., Maurer T., Gafita A., Kronke M., Haller B., Weber W. A., **Eiber M.**, Rauscher I. (2020). Pre-test (68)Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model. *EJNMMI Res*, 10(1), 6. doi:10.1186/s13550-020-0595-5
20. Kroenke M., Mirzoyan L., Horn T., Peeken J. C., Wurzer A., Wester H. J., Makowski M., Weber W. A., **Eiber M.**, Rauscher I. (2020). Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor related uptake and tumor positivity. *J Nucl Med*. doi:10.2967/jnumed.120.251447
21. Kroenke M., Wurzer A., Schwamborn K., Ulbrich L., Jooss L., Maurer T., Horn T., Rauscher I., Haller B., Herz M., Wester H. J., Weber W. A., **Eiber M.** (2020). Histologically Confirmed Diagnostic Efficacy of (18)F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. *J Nucl Med*, 61(5), 710-715. doi:10.2967/jnumed.119.234906
22. Lenis A. T., Pooli A., Lec P. M., Sadun T. Y., Johnson D. C., Lebacle C., Fendler W. P., **Eiber M.**, Czernin J., Reiter R. E., Calais J. (2020). Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naive Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. *Eur Urol Oncol*. doi:10.1016/j.euo.2020.08.012
23. Lückerrath K., Stuparu A. D., Wei L., Kim W., Radu C. G., Mona C. E., Calais J., Rettig M., Reiter R. E., Czernin J., Slavik R., Herrmann K., **Eiber M.**, Fendler W. P. (2018). Detection Threshold and Reproducibility of (68)Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. *J Nucl Med*, 59(9), 1392-1397. doi:10.2967/jnumed.118.207704

24. Lückcrath K., Wei L., Fendler W. P., Evans-Axelsson S., Stuparu A. D., Slavik R., Mona C. E., Calais J., Rettig M., Reiter R. E., Herrmann K., Radu C. G., Czernin J., **Eiber M.** (2018). Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. *EJNMMI Res*, 8(1), 96. doi:10.1186/s13550-018-0451-z
25. Oh S. W., Wurzer A., Teoh E. J., Oh S., Langbein T., Kronke M., Herz M., Kropf S., Wester H. J., Weber W. A., **Eiber M.** (2020). Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, (18)F-rhPSMA-7, in Patients with Prostate Cancer. *J Nucl Med*, 61(5), 702-709. doi:10.2967/jnumed.119.234609
26. Pfob C. H., **Eiber M.**, Luppä P., Maurer F., Maurer T., Tauber R., D'Alessandria C., Feuerecker B., Scheidhauer K., Ott A., Heemann U., Schwaiger M., Schmaderer C. (2018). Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. *EJNMMI Res*, 8(1), 17. doi:10.1186/s13550-018-0370-z
27. Rauscher I., Duwel C., Haller B., Rischpler C., Heck M. M., Gschwend J. E., Schwaiger M., Maurer T., **Eiber M.** (2018). Efficacy, Predictive Factors, and Prediction Nomograms for (68)Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. *Eur Urol*, 73(5), 656-661. doi:10.1016/j.eururo.2018.01.006
28. Rauscher I., Fendler W. P., Hope T. A., Quon A., Nekolla S. G., Calais J., Richter A., Haller B., Herrmann K., Weber W. A., Czernin J., **Eiber M.** (2020). Can the Injected Dose Be Reduced in (68)Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? *J Nucl Med*, 61(2), 189-193. doi:10.2967/jnumed.119.227207
29. Rauscher I., Kronke M., König M., Gafita A., Maurer T., Horn T., Schiller K., Weber W., **Eiber M.** (2020). Matched-Pair Comparison of (68)Ga-PSMA-11 PET/CT and (18)F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. *J Nucl Med*, 61(1), 51-57. doi:10.2967/jnumed.119.229187
30. Robu S., Schmidt A., **Eiber M.**, Schottelius M., Gunther T., Hooshyar Yousefi B., Schwaiger M., Wester H. J. (2018). Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu- based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007. *EJNMMI Res*, 8(1), 30. doi:10.1186/s13550-018-0382-8
31. Seitz A. K., Rauscher I., Haller B., Kronke M., Luther S., Heck M. M., Horn T., Gschwend J. E., Schwaiger M., **Eiber M.**, Maurer T. (2018). Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. *Eur J Nucl*

Med Mol Imaging, 45(4), 602-612. doi:10.1007/s00259-017-3887-x

32. Sonni I., **Eiber M.**, Fendler W. P., Alano R. M., Vangala S. S., Kishan A. U., Nickols N., Rettig M. B., Reiter R. E., Czernin J., Calais J. (2020). Impact of (68)Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. *J Nucl Med*, 61(8), 1153-1160. doi:10.2967/jnumed.119.237602
33. Wang H., **Eiber M.**, Langbein T. (2020). A rare case of polyostotic fibrous dysplasia detected on (18)F-rhPSMA-7 PET/CT. *Eur J Nucl Med Mol Imaging*, 47(12), 2927-2929. doi:10.1007/s00259-020-04751-9
34. Wurzer A., Di Carlo D., Herz M., Richter A., Robu S., Schirrmacher R., Mascarin A., Weber W., **Eiber M.**, Schwaiger M., Wester H. J. (2021). Automated synthesis of [(18)F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions. *EJNMMI Radiopharm Chem*, 6(1), 4. doi:10.1186/s41181-021-00120-5
35. Wurzer A., Di Carlo D., Schmidt A., Beck R., **Eiber M.**, Schwaiger M., Wester H. J. (2020). Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors. *J Nucl Med*, 61(5), 735-742. doi:10.2967/jnumed.119.234922
36. Yusufi N., Wurzer A., Herz M., D'Alessandria C., Feuerecker B., Weber W. A., Wester H. J., Nekolla S. G., **Eiber M.** (2020). Comparative preclinical biodistribution, dosimetry and endoradiotherapy in mCRPC using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T. *J Nucl Med*. doi:10.2967/jnumed.120.254516